OnBoard Winter 2016 - page 32

Frank Florio is President, BD Canada and a member of the
Human Health and Sciences Committee, part of the Toronto
Region Board of Trade’s
TO Health!
cluster development
initiative. Florio acknowledges that healthcare is a field
where technology innovation has long existed, but that
the healthcare system also presents inherent barriers to
realizing the maximum benefits from new innovations.
It is complex, delivered in silos and under great financial
pressures. The company believe innovation in this
environment should be looked at in all forms.
Florio points out that health care innovation is rightly
focused on using technology or systems to improve on
the current standard of medical care, while lowering
costs and reducing risks to the patient. More recently,
“smart” innovations that enable rapid and predictive
data collection have also entered the health care system.
For Florio, that’s good news: “If you can free up money,
technology and information in the system, the potential
for mass benefits are remarkable.”
Florio is clear that BD has always been a part of
innovation in the industry, but emphasizes that in the
past five years, BD has “made innovation the lifeblood of
the organization.” The trigger was the financial crisis of
2007, the impact of which set the healthcare market back
years. By 2010, consequent revenue losses and slow
growth were adding to pressures on the industry.
BD was no exception. BD’s executive management
acknowledged that repeating the same strategies
was not going to yield new results. BD decided to
rethink innovation on a global basis. “We went back to
school, in a sense,” says Florio, describing a dedicated
leadership team that took its management through
a program of learning and training. They looked at
what higher performing companies were doing on the
innovation front. They dove into the latest case studies in
management science. And they drew upon their long-time
connection with Harvard Business School to help reset
their strategy with a new approach and a new mandate.
Five years on, BD Canada is embracing innovation
wherever it can be found and investing in breakthrough
technologies, services and acquisitions.
One example is found in their diagnostics business. The
microbiology lab infrastructure in Canada (and globally)
has long employed a manual process of laboratory work,
streaking plates in order to identify, isolate and assess
disease. BD has automated this entire process. The benefits
to a business are easy to see: increased labour cycle;
digitization of results; and an improved lab operation,
including less risk and enhanced safety. But the benefits to
patients are also plentiful: results are now generated and
sent to the doctor or hospital in just hours rather than days.
Patients diagnosed earlier can be treated sooner.
A product example is BD’s programmable smart infusion
pumps, accessible by a biometric access point. These
devices manage patient care and drug use from the
pharmacy to the patient, lowering the cost of drugs, making
them safer to use, and uploading data to a central health
record that can be shared with the doctor or pharmacy.
For more than 100 years, Becton, Dickinson and Company (BD) has been developing
and manufacturing a broad range of innovative medical supplies, devices, laboratory
equipment and diagnostic products. Headquartered in the U.S., this global medical
technology company serves healthcare institutions, life science researchers, clinical
laboratories, industry and the general public. BD Canada, a subsidiary of BD global,
has two Ontario offices, located in Oakville and in Mississauga.
BD Canada:
Advancing Innovations
in Healthcare
1...,22,23,24,25,26,27,28,29,30,31 33,34,35,36
Powered by FlippingBook